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ABSTRACT
Background: Topical methyl aminolevulinate photodynamic therapy (MAL-PDT) is highly effective for the
treatment of superficial basal cell carcinoma (sBCC). Current European treatment protocol requires two hos-
pital visits, which is costly and unpractical. The aim of this study was to evaluate the efficacy of fractionated
MAL-PDT, using two light fractions at 3 and 4h compared to illumination at 3 and 5 h after MAL-application.
Methods: Thirty patients were randomized into two groups. The first group received illumination at 3 and
4 h (20þ 55 J/cm2) after MAL-application (3/4 group). In the other group, two light fractions were
performed at 3 and 5 h (20þ 55 J/cm2) after MAL-application (3/5 group). The lesion response was eval-
uated at 3 and 12months posttreatment.
Results: In the 3/5 group, 70.0% showed a complete response (CR) at 3months compared to 63.6% in
the other group. At 12months, 100% showed a CR in the 3/5 group compared to 80.0% in the other
group. However, most failures/recurrences were eventually due to the presence of a more aggressive BCC
subtype, mostly caused by sampling error of the primary punch biopsy.
Conclusion: Single day protocol for MAL-PDT for sBCC is feasible and this study shows promising results.
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Introduction
Basal cell carcinoma (BCC) is the most common type of skin
cancer with an increasing incidence worldwide, becoming an
important health problem accompanied with rising health care
costs (1–3). While nodular BCC (nBCC) is the most common type,
a significant increase in the superficial subtype is noticed (4).
Although surgery is an appropriate treatment option, superficial
BCC (sBCC) is also suitable for nonsurgical treatment modalities,
since it is easy accessible with topical treatment. Photodynamic
therapy has been recommended as a first-line treatment for sBCC
by an international consensus (5). Photodynamic therapy (PDT)
involves the application of a topical photosensitizer or its prodrug,
in most cases aminolevulinic acid (ALA) or its methylated ester
methyl aminolevulinate (MAL).
MAL is the photosensitising agent approved for PDT for sBCC
and/or nBCC (6). The current European protocol for MAL-PDT for
sBCC consists of two light fractions (37 J/cm2) 1 week apart,
repeated at 3months if required (5,7–9). However, the double pro-
cedure is unpractical and the required day care visits result in
high treatment costs (10). Therefore, a MAL-PDT protocol using
two illumination fractions on the same day would be more prac-
tical and cheaper.
In ALA-PDT, multiple studies have shown the benefit of splitting
the illumination into two light fractions over a single illumination
session (11–13). This is due to re-synthesis of PpIX during the dark
interval between two light fractions (14–16). Also in MAL-PDT,
there is re-synthesis of PpIX after illumination (17). Further studies
have tried to optimise fractionated ALA-PDT (18,19).
De Bruijn et al. (17) investigated the response of MAL-PDT
using a single- and a two-fold illumination scheme and compared
that to ALA-PDT in normal mouse tissue. Four hours after ALA or
MAL application, the skin was illuminated using either a single
light fraction (100 J/cm2) or a two-fold illumination scheme
(5þ 95 J/cm2) with a 2-h interval. They showed that fractionated
illumination did not enhance the clinical efficacy of MAL-PDT, as
was the case when using ALA. However, the optimum illumination
scheme for MAL-PDT is 3 h after application and not 4, as is the
case in ALA-PDT (20). Furthermore, this study was performed on
normal mouse tissue, and not on human tumor tissue and MAL is
known to be more tumor selective than ALA (21,22).
Therefore, the aim of this study was to evaluate fractionated
illumination of MAL-PDT in patients with sBCC lesions. We com-
pared two light fractions (20þ 55 J/cm2) of MAL-PDT with 1 or 2 h
interval: illumination at 3 and 4 h compared to illumination at 3
and 5 h after MAL-application. The total light dose was 75 J/cm2,
according to the standard MAL-PDT protocol for sBCC.
Furthermore, we studied the accuracy of histological examination
in sBCC punch biopsies for detecting the correct BCC subtype.
Materials and methods
This is a prospective, single-blinded, randomized multicenter pilot
trial, which was performed from June 2013 to October 2016 at
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the Radboud University Medical Center (Radboudumc), Nijmegen
and Maxima Medical Center (MMC), Eindhoven, the Netherlands.
The study has full ethical approval (NL41859.091.12) and was
executed according to the Declaration of Helsinki.
Study population
Eligible patients were those above the age of 18 years with a
histological proven (3mm punch biopsy) primary sBCC were
included. From each patient, one sBCC was included. Exclusion
criteria were patients with a known allergy to MAL or related com-
pounds, participation in other clinical studies, received treatments
in the last 12weeks for skin cancer in the area to be treated,
usage of chronic immunosuppressive medication and patients
who were pregnant or breastfeeding.
Intervention
Patients were randomized into two groups in a 1:1 ratio using a
sealed envelope system generated by a research nurse. The first
group received illumination at 3 and 4 h (3/4 group) after MAL
cream application. The second group was illuminated at 3 and 5 h
(3/5 group) after application of MAL. No control group with illumi-
nations 1 week apart was used, as many studies have analyzed
the effect of this already approved protocol. Randomization
occurred prior to pretreatment of the lesion. The research phys-
ician, who enrolled the patients and assessed the lesion response,
was blinded to the assigned treatment. Patients and treating
physicians were not masked for the assigned therapy. Lesion sizes
were determined clinically. An ellipse formula (pab/4) was used to
calculate the lesion area from the smallest (a) and largest dimen-
sion (b).
MAL-PDT treatment protocol
Salicylic acid (10%) in petrolatum daily for 1 week or an adhesive
dressing (DuoDERMVR , ConvaTec Inc., Deeside, UK) was applied
prior to PDT if necessary. A MAL cream was used (MetvixVR ,
160mg/g, Galderma). First, a layer of MAL cream (approximately
1mm thick) was applied to the lesion and to the surrounding
10mm of normal skin. The tumor site was covered with an adhe-
sive, occlusive dressing (TegadermVR , 3M Health Care Ltd,
Bracknell, UK) and tinfoil to prevent influence of light. Three hours
after application, the cream was wiped off and the tumor was illu-
minated using the 630 nm AktiliteVR CL 128 lamp (Galderma). The
lesion including a margin of at least 10mm was illuminated. The
first illumination session took around 4min (20 J/cm2) and the
second session took around 12min (55 J/cm2). The possibility of
pain sensations during illumination was explained to the patients
and they were given the choice of no medication or
Acetaminophen (1000mg the day before, in the morning of and/
or 1 h before treatment). The Visual Analogue Scale (VAS) score
was used to assess the extent of pain that the patients endured
during illumination.
Lesion response
The lesions were clinically evaluated at 3 and 12months after
treatment. At each visit, the clinical treatment response (complete,
partial, and no response), lesion reduction and possible adverse
events were evaluated. Complete responses (CR) were defined as
100% clinical visual clearance of the sBCC. Partial responses (PR)
were defined as 50% reduction in the greatest diameter. No
responses (NR) were assessed as <50% reduction in the greatest
diameter. Photographs were taken at each follow up visit, unless
no change was observed. A punch biopsy was performed in case
of suspicion of a residual or recurrent BCC. If necessary, the choice
of an additional treatment was determined by the treat-
ing physician.
Histopathological examination process
During the study, all punch biopsies were routinely histological
examined with hematoxylin and eosin (H&E) stained tissue sec-
tions obtained from one level (at approximately 1000 mm).
Superficial BCCs were histologically defined as nests of basaloid
cells residing high in the dermis, usually in a multifocal pattern
(23). After the PDT study, all punch biopsies were sectioned in
four additional levels with an interval of 200 mm, in order to evalu-
ate whether more aggressive BCC subtypes might have been
missed using the routine protocol. After every 200 mm, 10 sections
of 4 mm each were sectioned of which two sections were stained
with H&E and evaluated by a pathologist-in-training (G.J.K.) and
pathologist (W.A.M.B.). BCC subtype classification was based on
the Dutch guideline (24). Tumor thickness was evaluated by meas-
uring the basaloid nest from the stratum granulosum up until the
deepest point of invasion.
Statistical analysis
Descriptive statistics, including median and range for continuous
variables and percentages for categorical data, were used to
explore patient and tumor characteristics. The Mann–Whitney
U-test and Fisher’s exact test were used to compare continuous
and categorical variables between groups, respectively. The
Spearman’s rank-order correlation was used to assess whether
there was an association between the amount of Acetaminophen
used prior to illumination and the VAS score after the first and
second illumination. In case a more aggressive BCC subtype was
detected in the punch biopsies, that were sectioned in additional
levels, follow up time was calculated from date of MAL-PDT treat-
ment to date of second treatment (excision or Imiquimod) or last
(poststudy) follow up (until January 2017). A p-value of .05 was
Table 1. Patient and tumor characteristics separated by treatment group.
Patient and tumor
characteristics
Illumination at
3 and 4 h (n¼ 11)
Illumination at
3 and 5 h (n¼ 10)
Gender
Male 6 (54.5) 3 (30.0)
Female 5 (45.5) 7 (70.0)
Age (years) 67 [49–81] 67 [45–86]
Fitzpatrick skin type
I 3 (27.3) 2 (20.0)
II 8 (72.7) 7 (70.0)
III 0 1 (10.0)
IV 0 0
Location BCC
Head and neck area 0 0
Upper extremities 1 (9.1) 2 (20.0)
Trunk 7 (63.6) 5 (50.0)
Lower extremities 3 (27.3) 3 (30.0)
sBCC lesion size (mm2) 78.5 [39.3–176.7] 78.5 [47.1–188.5]
Pretreatment sBCC
No 1 (27.3) 8 (20.0)
Salicylic acid 10% in vaseline 1 (9.1) 0
Duoderm 7 (63.6) 8 (80.0)
sBCC: superficial basal cell carcinoma. Continuous variables are displayed by
median and [range], categorical variables are displayed by absolute counts
and (proportion).
JOURNAL OF DERMATOLOGICAL TREATMENT 195
regarded statistically significant. Statistical analyses were per-
formed using IBM SPSS Statistics 22.0 (SPSS Inc., NY).
Results
Between June 2013 and July 2015, 30 patients with sBCCs were
enrolled; 16 patients of the Radboudumc and 14 of the MMC.
Eight patients were excluded due to nonadherence to the proto-
col [no punch biopsy obtained (n¼ 6), more than one lesion per
patient illuminated (n¼ 2)] and one patient was lost to follow up.
The remaining 21 patients were included in the analyses. Patient
and tumor characteristics were comparable in both groups
(Table 1).
In 3 months posttreatment, both groups showed CR rates
between 63.6 and 70.0% (Table 2). In the 3/4 group, 7 out of 11
sBCCs (63.6%) showed a CR after 3months, while three sBCCs
(27.3%) showed a PR (Table 2). A punch biopsy was obtained
from one of the partial responsive lesions, which revealed a sBCC.
This lesion was marked as a treatment failure (9.1%) and treated
with Imiquimod with a good effect. One lesion (9.1%) remained
the same size, but showed minimal erythema. This lesion was
listed as NR and was followed up. Seven out of 10 lesions (70.0%),
in the 3/5 group, showed CR after 3months. From two of the
three partial responsive lesions, punch biopsies were performed
and both revealed sBCCs. However, after surgical excision, both
lesions appeared to be mixed type BCCs. The other PR lesion was
followed up.
The CR rate after 12months was 80.0% (8/10) and 100% (8/8)
for respectively the 3/4 and 3/5 groups (Table 2). In the 3/4 group,
two BCCs showed PR (20.0%); one of them was detected at an
extra visit 5months after illumination. Punch biopsies from these
PR lesions revealed sBCCs (n¼ 2) of which one was a treatment
failure and the other one was a recurrence, since it showed a
complete response earlier at an extra visit 6months after illumin-
ation. After surgical excision of these lesions, one was diagnosed
as a sBCC. However, the other appeared to be a nBCC.
No statistical differences were noted between the groups at 3
and 12 months with respect to lesion responses and median
lesion size reduction. Although the data on lesion size reduction
from one patient, in the 3/4 group, was missing. The median VAS
scores after the first illumination were 3 and 4.5; and after the
second illumination 4 and 4 for the 3/4 and 3/5 group respect-
ively (Supplementary Table 1). No significant differences were
found in the median VAS scores between the two illumination
groups. There was no association between the amount
of Acetominophen used prior to the first illumination (r¼ 0.295,
p¼ .135) and the second illumination (r¼ 0.058, p¼ .777) and the
VAS-score. Moreover, no serious adverse events were reported
(Table 2).
Histopathological examination
Twenty-six punch biopsies (21 initial and 5 posttreatment biop-
sies) were available for additional sectioning (Table 3). In four
punch biopsies (three initial and one posttreatment biopsies),
other BCC subtypes were detected after additional sectioning.
They showed three nBCCs (Table 3; patients 6, 12, and 17) and
one mixed-type BCC with nodular and infiltrative components
(Table 3; patient 8). Two of these lesions (patients 6 and 8) were
treatment failures which were surgically excised. The median
follow-up time for these lesions, until their second treatment, was
612 d (range 276–947 d). The other two (patients 12 and 17) did
not show any clinical sign of treatment failure or recurrence after
treatment and therefore continued their (poststudy) routine der-
mato-oncological follow-up at their respective hospitals. The
median follow-up time (including time of follow up poststudy
until January 2017) for these lesions was 816 d (range 739–892 d).
Discussion
Current MAL-PDT treatment for sBCC requires two treatment
sessions on separate days, and repeated after 3months if neces-
sary (5,7–9). This requires at least two hospital visits, which is
unpractical and costly. Therefore, the purpose of this study was to
evaluate two different MAL-PDT protocols in which two light frac-
tions were performed on a single day, with 1 or 2 h interval.
Table 2. Results of biopsy-proven superficial basal cell carcinomas.
At 3 months At 12 months
Illumination at
3 and 4 h
Illumination at
3 and 5 h p-Value Total
Illumination at
3 and 4 h
Illumination at
3 and 5 h p-Value Total
Number of biopsy-proven sBCCs 11 10 – 21 10 8 – 18
Clearance of biopsy-proven sBCCs
Complete response (%) 7 (63.6) 7 (70.0) .757 14 (66.7) 8 (80.0) 8 (100) .110 16 (88.9)
Partial response (%) 3 (27.3) 3 (30.0) .890 6 (28.6) 2 (20.0) 0 .110 2 (11.1)
No response (%) 1 (9.1) 0 (0) .329 1 (4.8) 0 0 n.a. 0
Histological confirmation of response 1 (of the PR) 2 (of the PR) – 3 2 (of the PR) 0 – 2
Biopsy sBCC (n¼ 1) sBCC (n¼ 2) – 3 sBCC (n¼ 2) 0 – 2
Excision 0 s/nBCC (n¼ 1),
s/iBCC (n¼ 1)
– 2 sBCC (n¼ 1)a,
nBCC (n¼ 1)b
0 – 2
Treatment failure (%) 1c (9.1) 2 (20.0) .705 3 (14.3) 1b (10.0)
Excision: Nbcc
0 .762 1 (5.6)
Recurrence (%) 0 0 1.000 0 1a (10.0)
Excision: sBCC
0 .918 1 (5.6)
Median lesion size reduction
in mm2 [range]d
66.0 [0–176.7] 78.5 [18.9–188.4] .524 70.7 [0–188.4] 78.54 [39.3–176.7] 72.3 [47.1–106.8] .660 78.5 [39.3–176.7]
Median lesion size reduction
in percentage [range]d
100 [0–100] 100 [71.0–100] .645 100 [0–100] 100 [75.0–100] 100 [100–100] .346 100 [75–100]
iBCC: infiltrative basal cell carcinoma; n.a.: not applicable; nBCC: nodular basal cell carcinoma; sBCC: superficial basal cell carcinoma.
aRecurrence: presence of tumor tissue detected in follow-up after previous tumor clearance. This patient had a partial response at 3months, complete response at
an extra visit 6months, and partial response at 12months after illumination.
bIn one patient the partial response and treatment failure were detected at an extra visit 5months after illumination.
cTreated with Imiquimod, no excision occurred.
dMedian lesion reduction: compared to baseline.
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This is the first study using fractionated MAL-PDT in sBCCs in
human tissue. Overall, this study shows that two sessions of illu-
mination on a single day leads to CR rates of 80.0–100% at
12months. However, three of the five failures/recurrences were
eventually due to the presence of a more aggressive BCC subtype,
mostly caused by sampling error of the primary punch biopsy
and, in a lesser degree, to underdiagnosis of the primary
punch biopsy.
There are two prospective studies that used the approved
MAL-PDT protocol and had a follow-up at 3 and 12months
(25,26). They show comparable CR rates at 12months compared
to our study, although their studies included a larger study popu-
lation. Basset-Seguin et al. showed comparable results at 3months
when one single session of MAL-PDT (light dose 75 J/cm2) was
given after sBCCs were treated with MAL-cream 3h prior to illu-
mination (27). This leads to the question whether it might be eas-
ier to perform one illumination session of 75 J/cm2 instead of re-
illumination at 4 and 5 h. However, the incomplete responders in
the study of Basset-Seguin et al. were, thereafter, treated with 2
MAL-PDT illumination sessions 1 week apart at 3months. For that
reason, there is no information on the long-term effect of a single
illumination session. Therefore, a study with a larger population
comparing a single MAL-PDT illumination session (75 J/cm2) and
fractionated MAL-PDT (20þ 50 J/cm2) with a longer follow-up
period is recommended.
In this study, some lesions showed less erythema after PDT
compared to before treatment, or mild remaining erythema pos-
sible due to scarring of the biopsy location or after PDT treatment.
According to our strict definitions of ‘lesion response’, these
lesions were marked PR or NR. However, not all these lesions
were clinically suspect for a treatment failure or recurrence.
Therefore, not all of them were biopsied. This is also the reason
why some lesions, which appeared as PR or NR at 3months,
showed CR at 12months.
All adverse events that were reported in this study were in
accordance with other studies (25,28). No serious adverse reactions
occurred. Arits et al. showed in their study that serious adverse
events only occurred in patients treated with Imiquimod and 5-FU
but not in the MAL-PDT treatment group (25). More importantly, a
generally better cosmetic outcome is observed after PDT treatment
of sBCC compared to other treatment options (25,26). Furthermore,
the treatment regime for Imiquimod and topical 5-FU is intensive
and long (4–6weeks) (29). In daily practice, not all patients will be
motivated or able to apply a cream for such a long period. For
these patients, hospital-based treatments such as MAL-PDT and
surgical excision might be preferable. In case, both treatments can
take place during one visit, MAL-PDT may have the benefit over
surgical excision, especially when cosmetic outcome and problem-
atic healing sites are taken into consideration.
The five treatment failures/recurrences in the present study
were mostly due to the presence of a more aggressive BCC
subtype in the excision. In three lesions, other BCC subtypes
(nodular and infiltrative) were detected in the excision specimen.
Although, MAL-PDT is also effective in nBCC, poorer clearance
rates and higher recurrences were seen in these tumors compared
to sBCCs (26,30,31). Moreover, MAL-PDT is not registered for the
treatment of iBCC. Histological underdiagnosis of the primary
biopsy may have led to an increased number of treatment failures
Table 3. Histopathological evaluation.
Prior to illumination 3 months 12 months
Patients with
punch
biopsies
BCC subtype
detected in
first
punch biopsy
BCC
subtype(s)
detected in
additional
levels (with
tumor
thickness
in mm)
Treatment
effect
BCC subtype
detected in
second
punch biopsy
BCC subtype
detected in
additional
levels (with
tumor
thickness
in mm) Excision
Treatment
effect
BCC subtype
detected in
second
punch biopsy
BCC subtype
detected in
additional
levels (with
tumor
thickness
in mm) Excision
1 sBCC sBCC (0.21) CR – – – CR – – –
2 sBCC sBCC (0.33) CR – – – CR – – –
3 sBCC sBCC (0.23) CR – – – CR – – –
4 sBCC sBCC (0.22) PR sBCC sBCC (0.31) s/nBCC – – – –
5 sBCC sBCC (0.38) CR – – – CR – – –
6 sBCC nBCC (0.63) PR – – – PRa sBCCa sBCCa (0.31) nBCCa
7 sBCC sBCC (0.20) PR – – – PR sBCC sBCC (0.24) sBCC
8 sBCC sBCC (0.32) PR sBCC n/iBCC (0.63) s/iBCC – – – –
9 sBCC sBCC (0.28) CR – – – CR – – –
10 sBCC sBCC (0.45) CR – – – CR – – –
11 sBCC sBCC (0.35) CR – – – CR – – –
12 sBCC nBCC (0.70) CR – – – CR – – –
13 sBCC sBCC (0.41) CR – – – CR – – –
14 sBCC sBCC (0.20) CR – – – CR – – –
15 sBCC sBCC (0.17) CR – – – CR – – –
16 sBCC sBCC (0.25) PRb – – – CR – – –
17 sBCC nBCC (0.36) NRb – – – CR – – –
18 sBCC sBCC (0.18) CR – – – CR – – –
19 sBCC sBCC (0.09) CR – – – CR – – –
20 sBCC sBCC (0.15) CR – – – CR – – –
21 sBCC sBCC (0.37) PR sBCC sBCC (0.38) –Treated with
Imiquimod
with
good effect
– – – –
iBCC: infiltrative basal cell carcinoma; nBCC: nodular basal cell carcinoma; sBCC: superficial basal cell carcinoma. “–” denotes Punch biopsy or surgical excision was
not performed.
aThis punch biopsy was obtained at an extra visit 5months after illumination.
bNo additional treatments were given after the initial MAL-PDT treatment.
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due to undertreatment. In order to reduce this risk, additional sec-
tioning of the primary punch biopsy can be performed (32,33).
This might result in a more accurate diagnosis of the primary
punch biopsy for adequate treatment. In our study, additional sec-
tioning yielded the detection of four BCCs with a more aggressive
BCC component in the primary biopsies, which were initially diag-
nosed as sBCCs. Two of these lesions were treatment failures and
removed by surgical excisions. The other two did not show any
clinical signs of treatment failure/recurrence after MAL-PDT
(median follow up period more than 2 years). In these two lesions,
MAL-PDT seemed to be an effective treatment. A hypothesis for
this might be that MAL-PDT is more effective in nBCCs with a
small tumor thickness (Table 3; patient 17) compared to nBCCs
with a larger tumor thickness (patients 6 and 8). On the other
hand, one nBCC lesion with a large tumor thickness (patient 12)
had a good clinical effect after MAL-PDT (follow-up approximately
2 years). There is a chance that this lesion might recur after an
extended follow-up period, like in the study of Roozeboom et al.,
where they noticed recurrences 3 years after MAL-PDT (34).
Therefore, this patient remains in (poststudy) routine clinical fol-
low-up. Another hypothesis is that the most aggressive part of
the mixed type BCC was removed by the punch biopsy, leaving
only the superficial type which responded well to the MAL-
PDT treatment.
One mixed type BCC was not detected after additional section-
ing of the primary punch biopsy (Table 3; patient 4). This may
have been a result of sampling error of the primary punch biopsy.
The usage of noninvasive diagnostic techniques, such as the
reflectance confocal microscopy (RCM), may reduce sampling
errors as they offer the possibility to image the whole lesion and
distinguish different BCC subtypes (35,36). Overall, various options
are available to reduce sampling errors resulting in higher
cost-effectiveness, because they prevent the need for repeated
biopsies and subsequent treatment.
In conclusion, this study shows that MAL-PDT, given in a two-
fold illumination scheme with 1 or 2 h interval, is feasible and
shows promising results in the treatment of sBCC. Moreover, our
study shows the added value of a more thorough histological
examination in detecting the BCC subtype(s) in punch biopsies.
The next step would be to perform a larger clinical study to evalu-
ate the benefit of fractionated MAL-PDT over a single MAL-PDT
session and the regular MAL-PDT protocol.
Trial registration
This trial was not registered in a trial registry because when this
study started (in 2013) it was not very common practice to
prospectively register trials. When future studies on this subject
are conducted, we will prospectively register these studies in a
trial registry.
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